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A B S T R A C T
Recent evidence suggests that the angiotensin converting enzyme (ACE) is present in skin. The real value of the deter-
mination of ACE activity as a clinical-biochemistry test for the diagnosis of psoriasis has not been attained. Serum and
tissue ACE were measured in 60 patients with psoriasis, 20 patients with lichen planus, 20 patients with seborrhoic der-
matitis and in 20 healthy individuals. The serum and tissue ACE activity was determined before and after therapy, us-
ing the spectrophotometric method and hippuryl-l-histidyl-l-leucine as a substrate. The results showed that serum ACE
activity before therapy was significantly increased in both groups – patients with psoriasis (p<0.001) and patients with
lichen planus (p<0,001) in comparison to healthy individuals. However, there were no significant differences in serum
ACE activity among patients with seborrhoic dermatitis and healthy individuals. After therapy, serum ACE activity sig-
nificantly decreased in both groups of patients with psoriasis and patients with lichen planus comparing it to the level
found in the control group. The values in both were similar. The tissue ACE activity in altered skin was significantly in-
creased only in the patients with psoriasis in comparison to uninvolved skin of these patients, as well as the skin of
healthy individuals. After therapy, there were no significant differences in tissue ACE activity between the treated skin
and the healthy skin. In conclusion, determination of tissue angiotensin converting enzyme activity can be used in the
differential diagnostic of indistinct clinical forms of psoriasis.
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Introduction
The renin angiotensin system (RAS) plays a crucial
endocrine role in the physiology of blood pressure and
electrolyte balance1. An increasing number of studies
suggest the existence of local angiotensin generating sys-
tems which operate, in whole or in parts, independently
of the circulating RAS2. These have been described for
brain, kidney, adrenal gland, testis, artery walls, heart,
and other tissues. Recent findings suggest that the com-
plete RAS is present in human skin and plays a role in
normal cutaneous homeostasis.
Angiotensin converting enzyme (ACE; kininase II, EC
3.4.15.1), one of the key elements of the RAS, is a zinc
metalloendopeptidase that is widely distributed on the
surface of endothelial and epithelial cells. ACE removes
the carboxy terminal dipeptide from the decapeptide an-
giotensin I to generate angiotensin II, a potent vasocon-
strictor, and degrades bradykinin, a vasodilator3–4.
Investigations of ACE in dermatology are very scarce
and little is known about the possible role of ACE in the
pathogenesis of skin diseases.
Raff et al.5 first found an increase of serum ACE in
patients with psoriasis, and this was confirmed by other
studies6–9. Recent studies have shown that ACE inhibi-
tors have been implicated in its cause. However, the
mechanism by which ACE inhibitors could cause a flare
up of the pre-existing disease is not clear.
However, no firm attitude on the determination of the
ACE activity as a clinical-biochemistry test for the diag-
nosis of psoriasis has been attained.
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An increase of level ACE was also found in the sino-
vial fluid7 in patients with psoriasis. Furthermore, there
are no published data on the ACE activity in the tissue of
skin except for a preliminary study in a low number of
patients with psoriasis10.
The effect of therapy on serum ACE activity in psoria-
sis has been examined only in a few studies. It was ob-
served that serum ACE activity decreased after therapy8.
In our recent study we also found the decrease of serum
ACE activity after treatment of the disease, and there
was no significant difference response between various
forms of treatment11.
Furthermore, the effect of therapy on tissue ACE ac-
tivity in patients with psoriasis was not studied.
The aim of the present study was to investigate serum
and tissue ACE activity in patients with psoriasis and the




The sample of subjects included 60 patients suffering
from psoriasis; 20 patients suffering from lichen planus;
20 patients with seborrhoic dermatitis, while 20 subjects
served as Control. The patients with diseases that might
influence the serum ACE activity (sarcoidosis, arterial
hypertension, pulmonary tuberculosis, hepatic diseases,
diabetes mellitus, and others) were excluded from the
study. Patients with psoriasis included 60 patients of
both sexes, aged 35–45 years, who were being medically
treated. The diagnosis of psoriasis was made on the basis
of a clinical examination and biopsy findings at the De-
partment of Dermatology, the University Clinic Centre in
Sarajevo. Patients with psoriasis received matching ei-
ther local therapy (10% ol. candidi, 5–10% salicylvaseli-
ne), photochemotherapy (8-methoxypsoralen as photo-
sensibilisator in dose 0.6 mg/kg body weight) or cyto-
static therapy (methotrexate 25 mg per week, total dose
100 mg). The patients with lichen planus included 20 pa-
tients of both sexes (10 men and 10 women), aged 35–45
years, who were being medically treated. The diagnosis
of lichen planus was made on the basis of a clinical exam-
ination and biopsy findings at the Department of Derma-
tology, the University Clinic Centre in Sarajevo. The pa-
tients with seborrhoic dermatitis included 20 patients of
both sexes (10 men and 10 women), aged 35–45 years,
who were being medically treated. The diagnosis of sebo-
rrhoic dermatitis was made on the basis of clinical exami-
nation and biopsy findings at the Department of Derma-
tology, the University Clinic Centre in Sarajevo. The
control group consisted of subjects of both sexes (10 men
and 10 women), aged 35–45 years, who were healthy ac-
cording to their subjective and objective findings.
Laboratory and other analyses
Routine laboratory analyses, including erythrocyte
and leukocyte counts, erythrocyte sedimentation rate,
hematocrit, hemoglobin, urea, uric acid, creatinine, tri-
glycerides, cholesterol, and glucose levels, as well as a
complete urine analysis, were performed in each patient.
A biopsy of skin was taken in all patients with psoriasis
for a pathohystologic analysis
Serum and tissue sampling
Serum and tissue ACE activity was measured in pa-
tients with psoriasis before and after therapy. Blood sam-
ples for the determination of serum ACE activity were
taken from the cubital vein. After coagulation and cen-
trifugation at 2,000 g for 5 min, the serum was frozen at
–20 °C until analysis. After the biopsy all the tissues skin
samples were weighed and washed extensively with 0.9%
NaCl solution (4 °C) for blood elimination. The tissues
were placed in the mixture of sodium phosphate buffer
(0.065 mol/L, pH 8.3, and 0.5 mol/L NaCl; 50 mg/mL) and
stored at –20°C. The tissues were homogenized in a Tef-
lon coated Potter-Elvehjem homogenizer, adding one drop
of a nonionic surfactant (Nonidet P 40) to each samples.
After centrifugation at 4,000 g for 30 min, the supernates
were frozen at –25 °C until determination of ACE activity.
Measurement of ACE activity
Serum and tissue ACE was determined by the spec-
trophotometric method using hippuryl-l-histidyl-l-leuci-
ne (Sigma, St. Louis, Mo., USA) as a substrate (12), and a
Perkin Elmer 550 S spectrophotometer for optical read-
ings. The enzyme activity is expressed in units: 1 U cor-
responds to 1 nmol of hippuric acid released by hydroly-
sis of hippuryl-l-histidyl-l-leucine per minute and liter of
serum or 50 mg of the tissue.
Statistics
Serum ACE activity is expressed as mean values ±
SEM. Differences between the mean values were statisti-
cally compared using Student’s and paired t-test. Proba-
bility values of less than 0.05 were considered significant.
Finally as an methodological remark. We are aware of
the fact that we did not include data of the severity/size
of the psoririatic tensions, but we believe that since: (a)
we excluded patients with diseases that might influence
the serum ACE activity, and (b) we performed extensive
statistical analysis it did not influence our conclusions
significantly.
Results
Figure 1 shows the mean values of the serum ACE ac-
tivity in patients with psoriasis, lichen planus and sebo-
rroic dermatitis before and after treatment.
Serum ACE activity was significantly increased in
both patients with psoriasis (35.02 ± 2.07; X ± SEM;
p<0.001) and patients with lichen planus (35.90 ± 2.09;
p<0.001) before therapy in comparison to the healthy in-
dividuals (28.16 ± 1.70). However, there were no signifi-
cant differences in serum ACE activity among patients
with seborrhoic dermatitis before therapy (31.44 ± 2.79)
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and healthy individuals. After therapy, serum ACE activ-
ity significantly decreased in both patients with psoriasis
and patients with lichen planus to a level which was simi-
lar to the control group.
Figure 2 shows the tissue ACE activity in patients
with psoriasis.
The tissue ACE activity was significantly increased in
the skin lesions of the patients with psoriasis (4.14 ±
0.43); the mean activity was by 122% higher than in skin
of the healthy subjects (1.86 ± 0.16; p<0.0001). There
were no significant differences in the tissue ACE activity
between the uninvolved skin of the patients with psoria-
sis (2.25 ± 0.18) and the skin in healthy subjects.
Figure 3 shows the mean values of the tissue ACE ac-
tivity in patients with psoriasis, lichen planus and se-
borroic dermatitis before and after therapy.
Before treatment the ACE activity was increased in
the lesional skin of the patients with psoriasis in compar-
ison with the skin of the control group (p<0.001). How-
ever, the tissue ACE activity in the skin lesions of both
the patients with lichen planus and the patients with
seborrhoic dermatitis was similar to the skin of the con-
trol group.
The effect of treatment on the tissue ACE activity in
patients with psoriasis is also shown in figure 3. The tis-
sue ACE activity in the skin lesions decreased by 46%af-
ter treatment in the patients with psoriasis in compari-
son with the mean activity before therapy (p<0.001).
Discussion
Conflicting data concerning the presence of enhanced
serum angiotensin-converting (SACE) activity in psoria-
sis are reported in literature13–15. Our study clearly showed
that the mean serum ACE activity is significantly in-
creased in both groups of patients with psoriasis and pa-
tients with lichen planus in comparison with healthy
subjects. These results are in accordance with previous
studies6–9. However, no significant difference in the se-
rum ACE activity was observed between the patients
with dermatitis seborrhoica and the healthy individuals.
In addition, our earlier study showed no significant dif-
ferences in the serum ACE activity in the different clini-
cal forms of psoriasis16. The presented results indicate
that a determination of the serum activity cannot be
helpful in differential diagnosis of psoriasis and for a dif-
ferentiation of the clinical forms of psoriasis.
After the treatment, the serum ACE activity in our
study decreased in both groups of patients with psoriasis
and patients with lichen planus and reached a level,
which was not significantly different from that in the
control group. Also, the results of our previous studies
showed that there was no significant different response
among the various forms of treatment of patients with
psoriasis11. This implies that the serum ACE activity in
these patients might be used as an adjunct in the moni-
toring of the disease activity and may be one of the most
important parameters in the assessment of the used
therapy effects.






























Fig 1. Serum ACE activity (mean ± SEM) in patients with psori-
asis, lichen planus and seborrhoic dermatitis before and after
therapy (Control – control group; Psoriasis – patients with psori-
asis; Lichen planus – patients with lichen planus; Seborrhoic
dermatitis – patients with seborrhoic dermatitis; NS – not signif-
icant: p – probability; * – in comparison with control group; ** –



























Fig 2. Tissue ACE activity (mean ± SEM) in patients with psoria-
sis (Control – control group; Uninvolved skin – Uninvolved skin
of patients with psoriasis; Lesional skin – Lesional skin of pa-



































Fig. 3. Tissue ACE activity (mean ± SEM) in patients with psori-
asis, lichen planus and seborrhoic dermatitis before and after
therapy. (Control – control group; Psoriasis – patients with psori-
asis; Lichen planus – patients with lichen planus; Seborrhoic
dermatitis – patients with seborrhoic dermatitis (N=20; 10 men
Our study also shows that the tissue ACE activity was
significantly increased in the skin lesions of the patients
with psoriasis in comparison to the skin of healthy indi-
viduals. However, we did not find any alterations of the
tissue ACE activity in either groups of patients with li-
chen planus and the patients with seborrhoic dermatitis.
Our results pointed to the possibility that the determina-
tion of tissue ACE activity can be used at the differential
diagnosis of indistinct clinical forms of psoriasis.
The mechanism responsible for the increase of the se-
rum ACE activity in psoriasis is not clear. Recent studies
have demonstrated that ACE inhibitors could induce or
exacerbate psoriasis17–22. Since the administration of
ACE inhibitors would result in increased levels of sub-
stance P, Abraham and Farber23 suggest that ACE inhibi-
tors could provoke an exacerbation of psoriasis by en-
hancing the substance P-induced neuronal inflammation
in the skin. In addition, several reports suggest that sub-
stance P, through neuronal inflammation, plays a key
role in psoriasis24–25. Some authors suggest a build-up of
bradikinin as a possible cause of flare of the disease dur-
ing the treatment with ACE inhibitors. Furthermore, it
is well known that vascular ACE is an ectoenzyme mai-
nly expressed in the endothelial cells. In addition, a solu-
ble ACE is found in serum, which is presumably derived
from the membrane-bound form26. Since it has been sug-
gested that there is a widespread abnormality of the cap-
illaries in the skin of patients with psoriasis27, we believe
that damage to the blood vessel endothelium during pso-
riasis might be responsible at least for a higher release of
ACE from vascular endothelium in the blood. Also more
capillaries are perfused in both plaque and uninvolved
psoriatic skin then in the normal skin, and capillaries in
the psoriatic plaque skin are much larger than in normal
skin28. Thus, the increased blood flow in the psoriatic
plaque29 might be an additional causative factor for the
increased enzyme release in the blood. However, in our
presented study we have not found any significant differ-
ence in the tissue ACE activity between the uninvolved
skin of patients with psoriasis and the skin in healthy
subjects. Although the role of locally generated Ang-II is
not well established, we believe that it may be involved in
the development of psoriatic plaque. These data do not
show whether the increase of ACE activity in the skin le-
sions of patients with psoriasis is a primary process hav-
ing a pathogenic role or is only a secondary result of some
independent process. Obviously, this is the main question
that should be answered in further investigations.
In future studies it will be interesting to evaluate the
eventual influence of the estrogen level on the sensitivity
and specificity of a tissue ACE activity, but also to use
eventual multivariate analysis of the differences which
are showed to be statistically superior to univariate me-
thods we used herein30–31.
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SERUMSKI I TKIVNI ANGIOTENZIN-KONVERTIRAJU]I ENZIM U PACIJENATA S PSORIJAZOM
S A @ E T A K
U posljednje vrijeme postoje dokazi kako je angiotenzin-konvertiraju}i enzim (ACE) prisutan u ko`i. Me|utim, va-
ljanost procjene ACE aktivnost kao klini~kog biokemijskog testa za dijagnozu psorijaze jo{ nije utvr|ena. Serumski i
tkivni ACE mjeren je kod 60 pacijenata sa psorijazom (P), 20 pacijenata s lichen planus-om (LP) i 20 pacijenata koji su
bolovali od seboroi~nog dermatitisa (SD), kao i kod 20 zdravih pojedinaca koji su slu`ili kao kontrolna grupa (K). Kod P,
LP i SD mjerenja su provedena prije i nakon terapije spektrofotometrijski uz upotrebu hippuryl-l-histidyl-l-leucine kao
supstrata. Rezultati su pokazali kako je serumska ACE aktivnost prije terapije bila zna~ajno povi{ena kod P i LP, a u
usporedbi s K. Me|utim nisu utvr|ene zna~ajne razlike izme|u SD i K. Nakon terapije, serumska ACE aktivnost zna-
~ajno se smanjila kod P i LP. Tkivna ACE aktivnost oboljele ko`e bila je pove}anja samo kod P, a u usporedbi sa zdravom
ko`om kod istih pacijenata. Nakon terpaije nisu uo~ene zna~ajne razlike izme|u tretirane ko`e i zdrave ko`e. Zaklju-
~no. odre|ivanje tkivne ACE aktivnost mo`e se upotrebiti u razli~itim diferencijalnim dijagnozama klini~kih formi
psorijaze.
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